Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Potential Association Between Breast Cancer and RCC
  2. NLR, PLR, and SII Index May Predict Oncological Outcomes in Patients With Metastatic RCC Treated With Nivo+Ipi
  3. Association Between Gut Microbiota and Sunitinib-Induced Diarrhea in Metastatic RCC
  4. Outcomes of Cytoreductive Nephrectomy for Patients With Metastatic Renal Cell Carcinoma
  5. 2021 Top Story in Renal Cell Carcinoma: Combination Lenvatinib/Pembrolizumab
  6. NLR as a Prognostic Biomarker in Patients With Advanced RCC Treated With Avelumab Plus Axitinib or Sunitinib
  7. Safety and Efficacy of Nivo + Ipi in Patients With Advanced RCC With Brain Metastases: CheckMate 920
  8. Referral and Adjuvant Treatment Patterns After Nephrectomy in High-Risk Locoregional RCC
  9. Immune Checkpoint Inhibitor Therapy vs Targeted Therapy for Advanced Renal Cell Carcinoma
  10. Oligoprogression and Its Implications in Treating Metastatic Tumor Sites

Elsewhere

Recently Updated